Ratings High Tide Inc. Canadian Securities Exchange

Equities

HITI

CA42981E1043

End-of-day quote Canadian Securities Exchange 04:30:00 16/02/2021 am IST 5-day change 1st Jan Change
0.84 CAD +9.09% Intraday chart for High Tide Inc. -16.00% +229.41%

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
  • The stock, which is currently worth 2024 to 0.55 times its sales, is clearly overvalued in comparison with peers.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company is highly valued given the cash flows generated by its activity.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Drug Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
+229.41% 173M -
+14.32% 2.88B
D+
+13.95% 1.75B -
+98.52% 678M -
+3.18% 478M -
+5.60% 112M -
+0.28% 99.47M - -
+44.94% 58.59M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW